[凝血功能障碍与2019冠状病毒病。应对不断变化的现实的建议]

[Coagulopathy and COVID-19. Recommendations for a changing reality].

作者信息

Riveros Dardo, Maymó Daniela, Laviano Julia, Fornillo Florencia Fornillo, Fernández José, Benzadon Ricardo, Solimano Jorge, Cacchione Roberto, Riera Leandro, Duarte Patricio, Cazap Nicolás, Gotta Daniel, García Altuve Juan, Valentini Ricardo, Dupont Juan

机构信息

Servicio de Hematología, Medicina Transfusional y Trasplante de Médula ósea, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires, Argentina. E-mail:

Servicio de Hematología, Medicina Transfusional y Trasplante de Médula ósea, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires, Argentina.

出版信息

Medicina (B Aires). 2020;80(5):505-511.

PMID:33048795

Abstract

The coronavirus disease 2019 (COVID-19) pandemic requires rapid medical responses. The risk of venous and arterial thromboembolism increases in critically ill patients with SARS-CoV-2 infection. There is a hypercoagulable state that includes elevated levels of D-dimer, with an increased risk of organ failure and increased mortality. The abnormalities described in hemostasis should be considered for therapeutic decision making. We analyzed the available scientific evidence for the therapeutic approach of coagulopathy in the course of the disease with the objective of designing realistic therapeutic recommendations aimed at reducing morbidity and mortality in patients with COVID-19.

摘要

2019年冠状病毒病（COVID-19）大流行需要迅速的医学应对措施。感染严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的重症患者发生静脉和动脉血栓栓塞的风险增加。存在一种高凝状态，包括D-二聚体水平升高，伴有器官衰竭风险增加和死亡率上升。在进行治疗决策时应考虑到止血方面所描述的异常情况。我们分析了有关该疾病过程中凝血病治疗方法的现有科学证据，目的是制定切实可行的治疗建议，以降低COVID-19患者的发病率和死亡率。